News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

CEO and Chairman of the Board in Egetis Therapeutics acquire shares

November 25, 2021

Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Nicklas Westerholm, CEO, and Thomas Lönngren, Chairman of the Board, have acquired shares in the company.

Nicklas Westerholm has acquired 50,933 additional shares, and Thomas Lönngren has acquired 65,129 additional shares. Nicklas Westerholm’s total holding now amount to 109,873 in addition to warrants and employee stock options. Thomas Lönngren’s total holding now amount to 165,129 shares.

The information was submitted for publication, through the agency of the contact person set out above,
at 2021-11-25, 08:00 CET.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com